Anemia: progress in molecular mechanisms and therapies

Anemia is a major source of morbidity and mortality worldwide. Here we review recent insights into how red blood cells (RBCs) are produced, the pathogenic mechanisms underlying various forms of anemia, and novel therapies derived from these findings. It is likely that these new insights, mainly arising from basic scientific studies, will contribute immensely to both the understanding of frequently debilitating forms of anemia and the ability to treat affected patients. Major worldwide diseases that are likely to benefit from new advances include the hemoglobinopathies (β-thalassemia and sickle cell disease); rare genetic disorders of RBC production; and anemias associated with chronic kidney disease, inflammation, and cancer. Promising new approaches to treatment include drugs that target recently defined pathways in RBC production, iron metabolism, and fetal globin-family gene expression, as well as gene therapies that use improved viral vectors and newly developed genome editing technologies.

[1]  Isaure Chauvot de Beauchêne,et al.  HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia , 2014, Nature.

[2]  E. Lander,et al.  MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13 , 2011, Proceedings of the National Academy of Sciences.

[3]  T. Graeber,et al.  An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.

[4]  D. Weatherall The inherited diseases of hemoglobin are an emerging global health burden. , 2010, Blood.

[5]  S. Goh,et al.  High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin , 2007, Nature Medicine.

[6]  V. Sankaran BCL 11 A by the Developmental Stage-Specific Repressor Human Fetal Hemoglobin Expression Is Regulated , 2008 .

[7]  W. Jelkmann Pathophysiology and Pharmacology of Erythropoietin , 1992 .

[8]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[9]  G. Kato,et al.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. , 2014, Hematology/oncology clinics of North America.

[10]  E. Hod,et al.  CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso‐occlusion during hemolytic transfusion reactions , 2011, The Journal of clinical investigation.

[11]  J. D. Engel,et al.  Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes , 2011, Proceedings of the National Academy of Sciences.

[12]  S. Rivella,et al.  Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. , 2013, The Journal of clinical investigation.

[13]  Matthew C. Canver,et al.  An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level , 2013, Science.

[14]  M. Cappellini,et al.  Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. , 2012, Blood.

[15]  V. Jha,et al.  Chronic kidney disease: global dimension and perspectives , 2013, The Lancet.

[16]  Richard T. Lee,et al.  Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors , 2014, Science.

[17]  S. Brown,et al.  Balancing act. , 1996, The Canadian nurse.

[18]  K. Finberg Striking the target in iron overload disorders. , 2013, The Journal of clinical investigation.

[19]  F. Locatelli,et al.  Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. , 2013, Blood.

[20]  D. Neuberg,et al.  Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. , 2013, Blood.

[21]  S. Chou Transfusion therapy for sickle cell disease: a balancing act. , 2013, Hematology. American Society of Hematology. Education Program.

[22]  A. D. de Brevern,et al.  A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. , 2010, American journal of human genetics.

[23]  N. Mohandas,et al.  Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. , 1984, The New England journal of medicine.

[24]  C. Witmer Hematologic manifestations of systemic disease (including iron deficiency, anemia of inflammation and DIC). , 2013, Pediatric clinics of North America.

[25]  G. Jennings Death by a Thousand Cuts [Book Review] , 2009 .

[26]  A. Fricot,et al.  An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia , 2014, Nature Medicine.

[27]  Yijun Yang,et al.  Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women , 2013, Journal of clinical pharmacology.

[28]  Charles B. Hall,et al.  Transferrin therapy ameliorates disease in β-thalassemic mice , 2010, Nature Medicine.

[29]  H. Nakauchi,et al.  Clonal Analysis Unveils Self-Renewing Lineage-Restricted Progenitors Generated Directly from Hematopoietic Stem Cells , 2013, Cell.

[30]  C. Bokemeyer,et al.  Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment , 2005, Oncology.

[31]  I. Macdougall,et al.  Peginesatide in patients with anemia undergoing hemodialysis. , 2013, The New England journal of medicine.

[32]  I. Macdougall New anemia therapies: translating novel strategies from bench to bedside. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  I. Macdougall,et al.  Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. , 2013, The New England journal of medicine.

[34]  S. Orkin,et al.  The switch from fetal to adult hemoglobin. , 2013, Cold Spring Harbor perspectives in medicine.

[35]  Michel Sadelain,et al.  Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin , 2000, Nature.

[36]  W. Jelkmann Physiology and Pharmacology of Erythropoietin , 2013, Transfusion Medicine and Hemotherapy.

[37]  E. Lander,et al.  Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. , 2012, The Journal of clinical investigation.

[38]  S. Rivella,et al.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production. , 2014, Hematology/oncology clinics of North America.

[39]  P. Newburger,et al.  Novel deletion of RPL15 identified by array-comparative genomic hybridization in Diamond–Blackfan anemia , 2013, Human Genetics.

[40]  H. Lodish,et al.  Transcriptional divergence and conservation of human and mouse erythropoiesis , 2014, Proceedings of the National Academy of Sciences.

[41]  Richard T. Lee,et al.  Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle , 2014, Science.

[42]  R. Nagel,et al.  Correction of Sickle Cell Disease in Transgenic Mouse Models by Gene Therapy , 2001, Science.

[43]  N. Raje,et al.  Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. , 2010, Current opinion in molecular therapeutics.

[44]  S. Rivella,et al.  IDENTIFICATION OF ERYTHROFERRONE AS AN ERYTHROID REGULATOR OF IRON METABOLISM , 2014, Nature Genetics.

[45]  Kiran Musunuru,et al.  Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. , 2014, The Journal of clinical investigation.

[46]  Huimin Zhao,et al.  Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. , 2014, Biotechnology and bioengineering.

[47]  K. Markianos,et al.  Rare complete loss of function provides insight into a pleiotropic genome-wide association study locus. , 2013, Blood.

[48]  C. Burt,et al.  The Human Perspective , 2015, Perspectives in biology and medicine.

[49]  V. Sankaran,et al.  Thalassemia: an overview of 50 years of clinical research. , 2010, Hematology/oncology clinics of North America.

[50]  P. Frenette,et al.  Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. , 2013, Hematology. American Society of Hematology. Education Program.

[51]  J. Małyszko New renal anemia drugs: is there really anything new on the horizon? , 2014, Expert opinion on emerging drugs.

[52]  D. Abraham,et al.  5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells †,‡ , 2005, British journal of haematology.

[53]  Christopher J. Schofield,et al.  Oxygen sensing by HIF hydroxylases , 2004, Nature Reviews Molecular Cell Biology.

[54]  F. Grosveld,et al.  Haploinsufficiency for the erythroid transcription factor KLF1 causes Hereditary Persistence of Fetal Hemoglobin , 2010, Nature Genetics.

[55]  S. Rivella,et al.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. , 2010, The Journal of clinical investigation.

[56]  Danielle A. Simmons,et al.  Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice , 2014, Nature Medicine.

[57]  T. Ganz,et al.  Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. , 2012, Blood.

[58]  T. Ganz Systemic iron homeostasis. , 2013, Physiological reviews.

[59]  Jérôme Larghero,et al.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.

[60]  P. Frenette,et al.  GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. , 2010, Blood.

[61]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[62]  Jacob C. Ulirsch,et al.  Altered Chromatin Occupancy of Master Regulators Underlies Evolutionary Divergence in the Transcriptional Landscape of Erythroid Differentiation , 2014, PLoS genetics.

[63]  R. Strieter,et al.  NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. , 2009, Blood.

[64]  S. Rivella,et al.  Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response. , 2013, The Journal of clinical investigation.

[65]  S. Orkin,et al.  Genome-wide association studies of hematologic phenotypes: a window into human hematopoiesis. , 2013, Current opinion in genetics & development.

[66]  S. Pai,et al.  Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[67]  V. Sankaran,et al.  Targeted therapeutic strategies for fetal hemoglobin induction. , 2011, Hematology. American Society of Hematology. Education Program.

[68]  Joel N Hirschhorn,et al.  Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation , 2010, Nature Genetics.

[69]  H. Hasle,et al.  Nathan and Oski’s Hematology of Infancy and Childhood , 2010 .

[70]  S. Rivella,et al.  Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. , 2008, Blood.

[71]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[72]  J. Segovia,et al.  Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  A. Grinberg,et al.  Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis , 2014, Nature Medicine.

[74]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[75]  I. Lamrissi‐Garcia,et al.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. , 2008, American journal of human genetics.

[76]  W. V. van IJcken,et al.  HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers. , 2014, The Journal of clinical investigation.

[77]  T. Golub,et al.  Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease , 2010, Proceedings of the National Academy of Sciences.

[78]  Philip D. Gregory,et al.  Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping , 2014, Cell.

[79]  Osamu Tanabe,et al.  Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction , 2013, Nature Medicine.

[80]  S. Milstein,et al.  An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. , 2013, Blood.

[81]  J. Price,et al.  Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. , 1998, Blood.

[82]  D. Gutsaeva,et al.  Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. , 2011, Blood.

[83]  Elizabeta Nemeth,et al.  IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. , 2004, The Journal of clinical investigation.

[84]  S. Orkin,et al.  Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. , 2011, Blood.

[85]  Richard T. Lee,et al.  Growth Differentiation Factor 11 Is a Circulating Factor that Reverses Age-Related Cardiac Hypertrophy , 2013, Cell.

[86]  O. Platt,et al.  Hydroxyurea for the treatment of sickle cell anemia. , 2008, The New England journal of medicine.

[87]  L. Naldini Ex vivo gene transfer and correction for cell-based therapies , 2011, Nature Reviews Genetics.

[88]  M. Gladwin,et al.  Erythroid DAMPs drive inflammation in SCD. , 2014, Blood.

[89]  Y. Kan,et al.  Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac , 2014, Genome research.

[90]  Chris Fisher,et al.  A functional element necessary for fetal hemoglobin silencing. , 2011, The New England journal of medicine.

[91]  Tamir Kanias,et al.  Hemolysis and cell-free hemoglobin drive an intrinsic mechanism for human disease. , 2012, The Journal of clinical investigation.

[92]  D. Lipschitz,et al.  Interferon‐γ exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development , 1995 .

[93]  M. Gladwin,et al.  Sickle-cell disease , 2010, The Lancet.

[94]  L. Bogun ANEMIA OF CHRONIC DISEASE , 2015 .

[95]  J. Palis Primitive and definitive erythropoiesis in mammals , 2013, Front. Physiol..

[96]  L. Usvyat,et al.  Anaphylaxis and hypotension after administration of peginesatide. , 2014, The New England journal of medicine.

[97]  Elisa Laurenti,et al.  Hematopoiesis: a human perspective. , 2012, Cell stem cell.

[98]  Ronald W. Barrett,et al.  Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.

[99]  Vanessa Taupin,et al.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo , 2010, Nature Biotechnology.

[100]  P. Frenette,et al.  Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. , 2007, Blood.

[101]  S. Karlsson,et al.  Gene therapy of Diamond Blackfan anemia CD34(+) cells leads to improved erythroid development and engraftment following transplantation. , 2008, Experimental hematology.

[102]  S. Perrotta,et al.  Hereditary spherocytosis , 2008, The Lancet.

[103]  M. Sadelain,et al.  Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. , 2000, Blood.

[104]  R. Bejar,et al.  Recent developments in myelodysplastic syndromes. , 2014, Blood.

[105]  S. Agarwal,et al.  Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia , 2011, Nature Medicine.

[106]  Allon M. Klein,et al.  Clonal dynamics of native haematopoiesis , 2014, Nature.

[107]  R. Paulson Targeting a new regulator of erythropoiesis to alleviate anemia , 2014, Nature Medicine.

[108]  Seth R Flaxman,et al.  A systematic analysis of global anemia burden from 1990 to 2010. , 2014, Blood.

[109]  Jie Li,et al.  Global transcriptome analyses of human and murine terminal erythroid differentiation. , 2014, Blood.

[110]  S. Orkin,et al.  Corepressor-dependent silencing of fetal hemoglobin expression by BCL11A , 2013, Proceedings of the National Academy of Sciences.

[111]  Wouter W van Solinge,et al.  The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. , 2005, Blood.

[112]  M. Weiss,et al.  Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia. , 2012, Blood.

[113]  Cong Peng,et al.  Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin Silencing , 2011, Science.

[114]  I. Macaulay,et al.  Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy , 2013, Nature.

[115]  Elizabeta Nemeth,et al.  Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. , 2011, The Journal of clinical investigation.

[116]  J. D. Engel,et al.  Fetal Globin Gene Repressors as Drug Targets for Molecular Therapies To Treat the β-Globinopathies , 2014, Molecular and Cellular Biology.

[117]  Stuart H. Orkin,et al.  Developmental and species-divergent globin switching are driven by BCL11A , 2009, Nature.

[118]  P. Dubus,et al.  Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors. , 2012, American journal of human genetics.

[119]  Philippe Joly,et al.  Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach , 2011, Nature Genetics.

[120]  J. Spivak The anaemia of cancer: death by a thousand cuts , 2005, Nature Reviews Cancer.

[121]  Richard van Wijk,et al.  The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis , 2005 .

[122]  P. Gregory,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[123]  S. Orkin,et al.  Nathan and Oski's hematology of infancy and childhood , 2013 .

[124]  E. Lander,et al.  Altered translation of GATA1 in Diamond-Blackfan anemia , 2014, Nature Medicine.